221 related articles for article (PubMed ID: 28561640)
1. Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer.
Planchard D; Remon J; Nowak F; Soria JC
Am Soc Clin Oncol Educ Book; 2017; 37():12-17. PubMed ID: 28561640
[No Abstract] [Full Text] [Related]
2. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
3. Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
Kim ES; Roy UB; Ersek JL; King J; Smith RA; Martin N; Martins R; Moore A; Silvestri GA; Jett J
J Thorac Oncol; 2019 Mar; 14(3):338-342. PubMed ID: 30709747
[No Abstract] [Full Text] [Related]
4. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
5. Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC).
Nellesen D; Dea K; Guerin A; Culver KW; Mutebi A; Dalal A
Am J Manag Care; 2018 Feb; 24(2 Spec No.):SP37-SP42. PubMed ID: 29689141
[No Abstract] [Full Text] [Related]
6. Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing.
Moore DA; Balbi KJ; Poskitt B; Bennett P
J Clin Pathol; 2022 Mar; 75(3):209-210. PubMed ID: 34168072
[No Abstract] [Full Text] [Related]
7. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
8. Promises and challenges in developing miRNA as a molecular diagnostic tool for lung cancer.
Cho WC
Expert Rev Mol Diagn; 2011 Nov; 11(8):763-6. PubMed ID: 22022936
[No Abstract] [Full Text] [Related]
9. The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer.
Ross K; Pailler E; Faugeroux V; Taylor M; Oulhen M; Auger N; Planchard D; Soria JC; Lindsay CR; Besse B; Vielh P; Farace F
Expert Rev Mol Diagn; 2015; 15(12):1605-29. PubMed ID: 26564313
[TBL] [Abstract][Full Text] [Related]
10. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
[TBL] [Abstract][Full Text] [Related]
12. Molecular markers for the diagnosis and prognosis of lung cancer.
Gazdar AF
Cancer; 1992 Mar; 69(6 Suppl):1592-9. PubMed ID: 1311627
[TBL] [Abstract][Full Text] [Related]
13. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma.
Ileana EE; Wistuba II; Izzo JG
Cancer J; 2015; 21(5):413-24. PubMed ID: 26389767
[TBL] [Abstract][Full Text] [Related]
14. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays.
El-Zein RA; Abdel-Rahman S; Santee KJ; Yu R; Shete S
Cytogenet Genome Res; 2017; 152(3):122-131. PubMed ID: 28898877
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors testing proposal for NSCLC patients during the COVID-19 pandemic.
Krawczyk P; Kowalski DM; Wojas-Krawczyk K; Dziadziuszko R
Expert Rev Anticancer Ther; 2021 Jun; 21(6):569-572. PubMed ID: 33724132
[No Abstract] [Full Text] [Related]
16. Predictive testing in non-small cell lung carcinoma.
Dundr P; Matěj R; Němejcová K; Bártů M; Stružinská I
Klin Onkol; 2021; 34(Supplementum 1):29-34. PubMed ID: 34154327
[TBL] [Abstract][Full Text] [Related]
17. Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
Zhou F; Moreira AL
Arch Pathol Lab Med; 2016 Dec; 140(12):1331-1337. PubMed ID: 27588333
[TBL] [Abstract][Full Text] [Related]
18. Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing.
Zer A; Cutz JC; Sekhon H; Hwang DM; Sit C; Maganti M; Sung M; Binnie M; Brade A; Chung TB; Kamel-Reid S; Paul N; Tsao MS; Waddell T; da Cunha Santos G; Patel M; Carter RF; Leighl NB
J Thorac Oncol; 2018 Jul; 13(7):1004-1011. PubMed ID: 29535011
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutation testing for squamous cell lung carcinoma.
Liam CK; Leow HR; Pang YK
J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
[No Abstract] [Full Text] [Related]
20. Genomic Testing in Lung Cancer: Past, Present, and Future.
Mascaux C; Tsao MS; Hirsch FR
J Natl Compr Canc Netw; 2018 Mar; 16(3):323-334. PubMed ID: 29523671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
